Modality
Degrader
MOA
IL-13i
Target
CD3
Pathway
NF-κB
ADPKD
Development Pipeline
Preclinical
~Mar 2022
→ ~Jun 2023
Phase 1
Sep 2023
→ Jan 2026
Phase 1Current
NCT04514218
2,184 pts·ADPKD
2023-09→2026-01·Completed
2,184 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-01-232mo agoPh2 Data· ADPKD
Trial Timeline
Q42024Q2Q3Q42025Q2Q3Q42026
P1/2
Complet…
Catalysts
Ph2 Data
2026-01-23 · 2mo ago
ADPKD
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04514218 | Phase 1/2 | ADPKD | Completed | 2184 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxaderotide | Johnson & Johnson | NDA/BLA | PI3Kα | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| Gozesotorasib | Bristol-Myers Squibb | NDA/BLA | HER2 | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| AMG-1919 | Amgen | Phase 2/3 | CDK2 | |
| Ribozanubrutinib | Regeneron | Phase 1 | CDK4/6 | |
| Miriglumide | Alnylam | Phase 3 | CD3 |